Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 2/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | CASP6 | P55212 | 1/20 | 0.39 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.38 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31001832 | 1.00 | NR4A2 (0.42) | NR4A2ALOX5CYP2A6ALDH1A1KDM4E | |
| SCHEMBL28017683 | 0.78 | ALOX5 (0.43) | NR4A2ALOX5ALDH1A1KDM4ENPC1 | |
| SCHEMBL1479681 | 0.77 | ALOX5 (0.42) | NR4A2ALOX5ALDH1A1KDM4ENPC1 | |
| SCHEMBL1107218 | 0.75 | ALOX5 (0.48) | NR4A2ALOX5ALDH1A1KDM4ENPC1 | |
| SCHEMBL8113780 | 0.75 | ALOX5 (0.41) | NR4A2ALOX5ALDH1A1KDM4ENPC1 | |
| SCHEMBL4710724 | 0.75 | ALOX5 (0.44) | NR4A2ALOX5ALDH1A1KDM4ENPC1 | |
| SCHEMBL306185 | 0.75 | HTT (0.42) | NR4A2ALOX5ALDH1A1KDM4ENPC1 | |
| SCHEMBL16023610 | 0.75 | ALOX5 (0.41) | NR4A2ALOX5CYP2A6ALDH1A1KDM4E | |
| SCHEMBL3483357 | 0.75 | ALOX5 (0.44) | ALOX5ALDH1A1KDM4ENPC1RAB9A | |
| SCHEMBL29153739 | 0.75 | ALOX5 (0.41) | NR4A2ALOX5ALDH1A1KDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250289830-A1 | KRAS INHIBITORS | ELI LILLY AND COMPANY | 2025-09-18 | — | — | US | disclosed |
| US-12351591-B2 | KRas inhibitors | ELI LILLY AND COMPANY (US) | 2025-07-08 | — | — | US | disclosed |
| EP-4499233-A1 | KRAS INHIBITORS | Eli Lilly and Company (US) | 2025-02-05 | — | — | EP | disclosed |
| US-20240043451-A1 | KRAS INHIBITORS | ELI LILLY AND COMPANY | 2024-02-08 | — | — | US | disclosed |
| WO-2023183585-A1 | KRAS INHIBITORS | ELI LILLY AND COMPANY (US) | 2023-09-28 | — | — | WO | disclosed |
| US-9556135-B2 | Amino-dihydrothiazine and amino-dioxido dihydrothiazine compounds as beta-secretase antagonists and methods of use | AMGEN, INC. (US) | 2017-01-31 | — | — | US | disclosed |
| EP-2426108-B1 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | METHYLGENE INC (CA) | 2016-08-10 | — | — | EP | disclosed |
| US-20150259308-A1 | AMINO-DIHYDROTHIAZINE AND AMINO-DIOXIDO DIHYDROTHIAZINE COMPOUNDS AS BETA-SECRETASE ANTAGONISTS AND METHODS OF USE | AMGEN INC. (US) | 2015-09-17 | — | — | US | disclosed |
| US-9018378-B2 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | METHYLGENE INC. (CA) | 2015-04-28 | — | — | US | disclosed |
| US-8906852-B2 | Inhibitors of protein tyrosine kinase activity | METHYLGENE INC. (CA) | 2014-12-09 | — | — | US | disclosed |
| EP-2183255-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING FUSED HETEROCYCLIC KINASE INHIBITORS | MethylGene Inc. (CA) | 2010-05-12 | — | — | EP | disclosed |
| US-20090286984-A1 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | Mirati Therapeutics, Inc. | 2009-11-19 | — | — | US | disclosed |
| WO-2009026720-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING FUSED HETEROCYCLIC KINASE INHIBITORS | METHYLGENE INC. (CA) | 2009-03-05 | — | — | WO | disclosed |
| EP-0604114-B1 | Diaryl 5,6-fusedheterocyclic acids as leukotriene antagonists | MERCK FROSST CANADA INC (CA) | 2000-05-03 | — | — | EP | disclosed |
| CN-1148389-A | Diaryl 5, 6-fused heterocyclic acids as leukotriene antagonists | MERCK FROSST CANADA INC (CA) | 1997-04-23 | — | — | CN | disclosed |
| EP-0737196-A1 | DIARYL 5,6-FUSED HETEROCYCLIC ACIDS AS LEUKOTRIENE ANTAGONISTS | MERCK FROSST CANADA INC. (CA) | 1996-10-16 | — | — | EP | disclosed |
| US-5472964-A | Diaryl 5,6-fused heterocyclic acids as leukotriene antagonists | MERCK FROSST CANADA, INC. (CA) | 1995-12-05 | — | — | US | disclosed |
| WO-1995018132-A1 | DIARYL 5,6-FUSED HETEROCYCLIC ACIDS AS LEUKOTRIENE ANTAGONISTS | MERCK FROSST CANADA INC. (CA) | 1995-07-06 | — | — | WO | disclosed |
| WO-1994014815-A1 | DIARYL 5,6-FUSEDHETEROCYCLIC ACIDS AS LEUKOTRIENE ANTAGONISTS | MERCK FROSST CANADA INC. (CA) | 1994-07-07 | — | — | WO | disclosed |
| EP-0604114-A1 | Diaryl 5,6-fusedheterocyclic acids as leukotriene antagonists | MERCK FROSST CANADA INC. (CA) | 1994-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286984-A1 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | MAP3K19, MAP3K9, MAP4K2 | NR4A2 3600/4885ALOX5 3397/4885CYP2A6 2042/4885 |
| US-20240043451-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | NR4A2 3210/4885ALOX5 4777/4885CYP2A6 2972/4885 |
| US-12351591-B2 | KRas inhibitors | KRAS, NRAS, HRAS | NR4A2 3210/4885ALOX5 4777/4885CYP2A6 2972/4885 |
| US-20250289830-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | NR4A2 3210/4885ALOX5 4777/4885CYP2A6 2972/4885 |
| US-20150259308-A1 | AMINO-DIHYDROTHIAZINE AND AMINO-DIOXIDO DIHYDROTHIAZINE COMPOUNDS AS BETA-SECRETASE ANTAGONISTS AND METHODS OF USE | BACE1, BACE2, APP | NR4A2 563/4885ALOX5 1254/4885CYP2A6 259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.